NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CoreWeave, Inc. (NASDAQ: CRWV) between March 28, 2025 and December 15, 2025, both dates inclusive (the “Class Period”), of the important March 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased CoreWeave securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. W ...

Donovan Jones is an IPO research specialist with 15 years of experience analyzing investment opportunities for U.S. IPOs.He also leads the investing group IPO Edge, which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates. Learn moreAnal ...

New York, New York--(Newsfile Corp. - February 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bath & Body Works, Inc. (NYSE: BBWI) between June 4, 2024 and November 19, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline.SO WHAT: If you purchased Bath & Body Works securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...

Funds investing in high -yielding stocks like Exxon Mobil, Ford, Coca-Cola and Walmart are blowing it out of the water. ...

Key Takeaways Snap-on is expected to post Q4 revenue growth of 1.6% and EPS growth of 0.8% versus last year.SNA benefits from rising miles driven, aging vehicles and higher repair complexity, boosting tool demand.Snap-on sees strength in RS&I and Tools, though macro uncertainty and cost inflation remain risks.Snap-on Incorporated (SNA) is likely to witness growth in its top and bottom lines when it reports fourth-quarter 2025 earnings on Feb. 5, 2026, before the opening bell. The Zacks Consensus Estimate fo ...

Key Takeaways AMD expects strong Q4 Data Center growth from EPYC processors and Instinct accelerators. Cloud hyperscalers tripled EPYC usage, now totaling over 1,350 public instances globally. Oracle and partners deploy AMD-powered AI superclusters and private cloud platforms. Advanced Micro Devices (AMD) is expected to have benefited from strong Data Center revenues in the fourth quarter of 2025. The company is set to release results on Feb. 3, 2026. The company continues to strengthen its footprint in the ...

If you want full access to all our reports, data, and investing ideas, join The Aerospace Forum , the #1 aerospace, defense, and airline investment research service on Seeking Alpha, with access to evoX Data Analytics, our in-house developed data analytics platform.I upgraded Leonardo DRS (NYSE: DRS ) stock to strong buy in November 2025. The stock has delivered a 23.7% return, outperforming the S&P 500’s 4.6% gain. So, the share price performance has been fully in line with my expectations. However, after ...

Skye Bioscience, Inc. (NASDAQ:SKYE) on Monday shared interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond proof-of-concept study of nimacimab.Skye Phase 2a clinical trial (NCT06577090) in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy).Interim Data SummaryThe blinded extension of the CBeyond study for combination cohorts ...

The market benchmark is looking skittish, a sign it could fit a pattern seen across financial markets of prices tending to stall or reverse near round numbers. ...

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive†or "the Company†) (NASDAQ: AQST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Aquestive announced on January 9, 2026, that, "As part of its ongoing review o ...